Title

A study protocol on assessing the acceptance and effectiveness of a digital adherence technology for TB preventive treatment in Bangladesh

Pushpita Samina[1,2], Md Rifat Haidar[1], Tasmia Ibrahim[1], Tanjina Rahman[1], Mohammad Shahnewaz Sarker[1], Syada Samsia Noor[1], Shahriar Ahmed[1], Mohammad Khaja Mafij Uddin[1], Senjuti Kabir[1], Sayera Banu[1*]

[1] icddr,b Dhaka, Bangladesh

[2] McMaster University, Canada

Corresponding author

E-mail: sbanu@icddrb.org

Funding

'Improving tuberculosis (TB) management at Narsingdi district in Bangladesh: Incorporating TB screening at Integrated Management of Childhood Illness (IMCI) corners and strengthening TB preventive treatment services' project is funded by the Stop TB partnership through the TB REACH WAVE-10 initiative.

Competing interests

The authors declare that they have not any competing interests. "iDOTS" is a software developed by the icddr,b IT team. The primary goal of "iDOTS" is to enable real-time monitoring of TPT enrolled contacts. The product is solely developed for this study only.

Abstract

Adherence to tuberculosis preventive treatment (TPT) remains a significant challenge in high-burden countries like Bangladesh, where approximately 44 million people are infected with latent tuberculosis. This study protocol describes a mixed-methods observational study to evaluate "iDOTS," a locally developed digital adherence technology adapted from 99DOTS, for monitoring and improving TPT adherence among adult household contacts of bacteriologically confirmed pulmonary TB patients. The study will be conducted in two districts in Bangladesh with similar geographical and societal characteristics, with Narsingdi as the intervention site and Manikganj as the control site. Applying the Unified Theory of Acceptance and Use of Technology (UTAUT), we will assess technology acceptance, feasibility, implementation challenges, and effectiveness through quantitative and qualitative approaches. The quantitative component will compare TPT adherence between iDOTS users and non-users, while qualitative interviews will explore user experiences and attitudes among healthcare providers and patients. Adherence will be verified through a combination of digital records, self-reports, and random isoniazid urine testing. With an estimated sample size of 422 patients and 77 healthcare providers, this study aims to generate evidence that if digital adherence technologies can strengthen TPT implementation in resource-limited settings. The findings will address critical gaps in the TPT cascade and inform strategies for scaling up TPT nationally, ultimately supporting global efforts to reduce the TB disease burden through effective preventive measures.

Introduction

The World Health Organization (WHO) defines latent tuberculosis infection (LTBI) as a state of persistent immune response to *Mycobacterium tuberculosis* antigens without any clinically manifested active tuberculosis (TB) [1]. Approximately one-quarter of the global population is estimated to be infected with latent TB infection. This latent phase can persist for a lifetime in otherwise healthy individuals. Reactivation occurs in about 5% to 15% of individuals, typically within two to five years following the initial infection. This reactivation process transforms a latent infection into active TB disease, thereby making individuals with latent TB infection a significant reservoir for new active tuberculosis cases [1]. To reduce the burden of TB disease, the WHO recommends the use of TB preventive treatment for the high-risk and close contact of bacteriologically positive pulmonary TB patients with latent TB infection. The recent TB preventive treatment guideline from the WHO recommends three shorter treatment regimens for latent TB infection treatment [2]. Despite being termed "shorter", these regimens require a minimum of three months of treatment, including three once-a-week doses of isoniazid and rifapentine (3HP), three daily doses of isoniazid and rifampicin (3HR), and four months of daily rifampicin (4R). The success in preventing TB disease and averting TB infection to diseases significantly depends on treatment adherence and completion. Moreover, as individuals with latent TB infection do not exhibit any clinical manifestations of TB disease, motivating healthy individuals to complete a 3-month or 4-month treatment regimen presents challenges at the implementation level [3, 4].

In addition, all member states are mandated by the WHO to report on the TB preventive treatment cascade, which includes data on the number of eligible populations, the number of populations under evaluation, the number of contacts with latent TB infection, the number of individuals starting treatment, and the number of individuals completing treatment. Since the implementation of TB preventive treatment for non-HIV-infected adult individuals is relatively new, the reporting systems are still not well-equipped in many countries with a high burden of TB. The reporting systems often fail to capture the adverse drug reactions among individuals undergoing TB preventive treatment. Therefore, there is a need to develop a reporting system that can encourage individuals to adhere to TB preventive treatment and assist in reporting adverse events and the treatment outcome.

Bangladesh is one of the countries with a high burden of TB, and it is estimated that approximately 26.7% of the total population (~44 million) is infected with latent TB infection [5]. Bangladesh started implementing TB preventive treatment for adult household contacts in 30 districts (out of 64 districts) in 2022 and gradually expanded nationwide. However, the country lacks a robust reporting system for overseeing TB preventive treatment adherence and completion. The National TB Control Program (NTP) solely focuses on self-reported treatment completion, and there is an absence of a

structured mechanism to support individuals in medication adherence, monitor their
compliance, or report any adverse events [6].

Various technological interventions, including digital adherence technology, have been
developed to monitor adherence to TB treatment [7]. One of the utilized technologies is
"99DOTS", a low-cost, cellphone-based digital adherence technology for TB treatment [8,
9]. While multiple studies have appraised the use of "99DOTS", most of these have
concentrated on adherence to standard TB treatment [9, 10]. Research examining the
adherence monitoring of TB preventive treatment through "99DOTS" is limited, primarily
focusing on specific high-risk populations such as HIV/AIDS patients and pediatric
contacts [11-13]. Limited evidence exists regarding the utilization of "99DOTS" or other
digital adherence technology for TB preventive treatment in non-HIV/AIDS adult contacts.

Drawing from the foundation of 99DOTS, the International Centre for Diarrhoeal Disease
Research, Bangladesh (icddr,b), has developed a digital adherence technology for TB
preventive treatment named "iDOTS." Its principal aim is to facilitate real-time monitoring
of TB preventive treatment-enrolled contacts. Through the "iDOTS" dashboard,
community health workers or medical assistants can supervise individual contacts as they
take their medication. Each contact is required to register with "iDOTS" and receive a
colored pouch containing medication and a printed phone number. Subsequently, the
contacts are mandated to call a specific toll-free number to confirm medication intake, and
upon completion, they receive a confirmation SMS from the server. This technology
empowers community health workers to identify non-adherent patients in real-time and
provide follow-up care promptly.

The proposed protocol seeks to evaluate the utilization of "iDOTS" to determine its
acceptance, feasibility, and effectiveness in enhancing TB preventive treatment outcomes
in Bangladesh. The objective is to improve the adherence and outcome of TB preventive
treatment among the eligible close contacts of bacteriologically confirmed pulmonary TB
patients through remote monitoring of real-time adherence records. The protocol outlines
how quantitative and qualitative data will be utilized to inform the acceptance, feasibility,
implementation, and effectiveness of "iDOTS" in improving TB preventive treatment
adherence in Bangladesh.

Materials and Methods

Study objectives

The primary objective of this study is to evaluate the role of "iDOTS" in the implementation
of TB preventive treatment in Bangladesh. The specific objectives are as follows:
1. To explore how the attitudes of users (both providers and beneficiaries) influence
the acceptance of "iDOTS" for adherence to TB preventive treatment in Bangladesh.

2. To assess the effectiveness of "iDOTS" in maintaining adherence and reporting
on TB preventive treatment at the individual level.
3. To document users' experiences and the benefits and challenges encountered
while implementing "iDOTS."
128

Study design

We have applied the "User Acceptance of Information Technology: Toward a Unified View
Theory" (UTAUT) to design this study. It is a modern theory that provides a helpful tool for
managers to understand the drivers of acceptance of a new information technology used
in health. It also helps assess the likelihood of success for new technology introduction and
design interventions (including training, marketing, etc.) targeted toward users who are less
interested in adopting new technology. The theory identifies four variables influencing the
"behavioral intention" of using a new technology [14]: performance expectancy, effort
expectancy, social influence, and facilitating conditions. In addition, during a pragmatic trial
of e-health interventions, evidence should also be collected on the organization, cost,
social, human, technological, clinical, legal, and ethical aspects [15].

We propose that our study be a mixed-method observation study, where we plan to use
quantitative data to collect evidence on the technological and clinical aspects and
qualitative data to get detailed information on the social and human aspects. With this
study, we want to compare the adherence to TB preventive treatment between the two
groups, users and non-users of "iDOTS" and capture the user experience before, during,
and after the intervention. We aim to collect both quantitative and qualitative data through
pre- and post-intervention exit interviews, which will help predict the acceptance of
"iDOTS". The quantitative analysis will help to understand the variation in the pattern of
acceptance with age, sex, and education. However, the quantitative analysis alone cannot
explain the causes behind the variation unless detailed information is collected through
user interviews. The qualitative study will help understand the challenges and identify
possible solutions to the quantitative study's findings. In addition, we want to capture users'
(both healthcare providers and individuals receiving TB preventive treatment) experience
that will supplement the effectiveness results. In a scenario where the effectiveness is high,
but the users are not satisfied, it will be challenging to scale up the technology unless their
issues are addressed. We also want to assess if the technology alone is a compelling
reminder or if they use any other method to remind themselves about the medicine. An in-
depth interview with the users will also give information on the quality of "iDOTS" and the
confidence and comfort of providers and patients in using "iDOTS". We will collect
qualitative and quantitative data concurrently to assess if the results of both data converge
or diverge.

Study setting

The adult household contacts are enrolled for TB preventive treatment through Upazila health complexes and district hospitals. Considering the implementation challenge and ethical constraints, we predicted that randomly assigning individuals to the intervention group would be challenging. While cluster randomization could have been a possible solution, the NTP in Bangladesh had a preference for an intervention district; based on their preference, we purposively selected the Narsigndi district as an intervention site. Considering the geographical and societal similarities, we selected the Manikganj district as a control site. Six directly observed treatment (DOT) centers placed at Upazila health complexes of Raipura, Monohardi, Belabo, Palash, Shibpur, and Sadar, and four DOT centres placed at Upazila health complexes of Ghior, Singair, Shibaloy, and Sadar hospital in Manikganj has been included as study sites.

Sample size

Sample size for quantitative data collection

The sample size for end-users
Considering the district demography, latent TB infection burden, and generalizability, we calculated the sample size as below:

$$n=\frac{Z_{\alpha/2}^2 \times p \times (1-p)}{d^2}$$

Where,
$Z_{\alpha/2}$ = 1.96 (Considering 95% confidence level and α is 0.05)
p= 0.50 (Proportion)
d= 0.05 (Precision of the estimate)
Considering data from our previous study on monitoring adherence to the standard TB treatment using a digital platform (unpublished data), we assume that approximately 50% of the TB preventive treatment-initiated individuals will consent to enroll for digital adherence. Based on the above formula, considering 5% absolute precision, a total of 384 participants will be needed. Considering a 10% refusal rate, the required sample size will be 422 to determine the adherence and outcome of TB preventive treatment among the eligible household contacts of bacteriologically confirmed pulmonary TB patients. We plan to sequentially enroll and survey all eligible participants identified during the screening activity from intervention sites. Recruitment will continue until we have identified 422 from intervention sites.

The sample size for healthcare providers

For the survey, the following Cochrane's formula is used to determine the required sample size

$$n = \frac{Z_{\alpha/2}^2 \times p \times (1-p)}{d^2}$$

Where,

$Z_{\alpha/2}$ = 1.96 (Considering 95% confidence level and α is 0.05)

p= 0.95 (Proportion)

d= 0.05 (Precision of the estimate)

The sample size assumes that 95% of healthcare providers reported that they had previous experience using a smartphone in a digital adherence technology evaluation study [16]. Based on Cochrane's formula, considering 5% absolute precision, a total of 73 healthcare providers will be needed, and considering a 5% refusal rate, the required sample size will be 77 healthcare providers to estimate the experiences issues of using "iDOTS".

Sample size for qualitative data collection

Qualitative interviews will be conducted with both end users and service providers prior to and following the intervention. Data collection will continue until saturation is achieved, ensuring a comprehensive understanding of participant experiences. Simultaneous data coding will be employed to monitor and identify the point at which saturation occurs, allowing for a rigorous and systematic analysis of the interview data.

Participant enrollment

The baseline data on TB preventive treatment eligibility in the Narsingdi district exhibited that in 2023, around 2800 individuals were enrolled for TB preventive treatment over 12 12-month period. Considering our 99DOTS pilot study, we assume that approximately 50% of the TB preventive treatment-initiated individuals will consent to enroll for digital adherence, which would be 1400. During the six-month enrolment period and considering enrolment criteria (90% eligibility), we could enroll 1400/2 = 700 X 85% = 595, i.e., approximately 600 eligible TB preventive treatment individuals. We will also enroll 600 participants as a control from another site (Manikganj) following the same criteria.

Participant selection

For the intervention group end users, all eligible adult (> 18 years) household contacts of people with bacteriologically positive pulmonary TB will be enrolled in the study following the national TB preventive treatment algorithm (Fig 1). The community healthcare workers will screen the eligible household contacts of people with TB (bacteriologically positive) for TB symptoms (chronic cough, fever, weight loss). The individuals with symptoms will be referred to facilities, and the physicians will evaluate them for TB disease with chest X-ray and GeneXpert. The asymptomatic individuals will be given a tuberculin skin test, and if the

241 test results are positive, they will be further evaluated with an X-ray. If there are changes
242 in the X-ray, the individuals will be evaluated for TB disease and enroll for the TB treatment.
243 The ones who do not have changes in chest X-ray are enrolled for TB preventive treatment.
244 The end-user participants for the control group will be enrolled following the same process.
245
246 For another group of users, healthcare providers, we will select the providers who are
247 directly involved in the implementation process of TB preventive treatment, including
248 community healthcare workers, medical technologists, TB and leprosy control assistants,
249 physicians, and healthcare managers (upazila health and family planning officer) from the
250 intervention group.
251

Implementation process

253
The study will have three phases. (Fig 2) illustrates the step-by-step process. In the first
phase (pre-intervention), the study assesses the users' attitudes toward "iDOTS". The
second phase is the implementation phase, and in the third phase (post-intervention), the
study will capture the outcomes and user experiences. Data are collected from the users
using demographic information questionnaires after obtaining informed written consent in
the first phase and stored in an in-house secured locker. We conduct in-depth interviews
with a selected group of individuals with semi-structured questions. The questionnaires are
focused on assessing users' attitudes towards "iDOTS". They are briefed about "iDOTS"
prior to the interviews. All interviews are conducted in Bangla and last for 30-45 minutes.
The interviews are recorded, transcribed, and translated into English. Users of "iDOTS"
also receive a document with instructions and a manual form to track the doses.
265
In the intervention group, the end users are enrolled for "iDOTS" and are given a document
with instructions and a manual form to track the dose. The "iDOTS" contains TB preventive
treatment medication in tailored colorful pouches containing a printed phone number on it.
The contacts are instructed to call the specific toll-free numbers from their pre-registered
number each time after taking the medication. The dialed call reaches a predesigned
automated call receiving system. It is linked to a well-designed tracking algorithm that
marks each enrolled participant's status as medication taken or skipped. The medical
technologist (MTs) who enroll and counsel the TB patients will check the "iDOTS"
dashboard designed for him/her every morning. If any individual misses a dose, the
technical assistant calls him /her to remind about the missing dose and counsels to
complete the treatment. In addition, a medication reminder SMS will be sent to the
participants from whom no call was received on a particular day from the specified number
until 10.00 PM at night.
279
To assess the accuracy of the call and adherence, we randomly test the participant's urine
using a strip-based testing (IsoScreen assay) kit to examine the presence of isoniazid (a
TB preventive treatment drug). We maintain a calendar to randomly select the individuals

for urine tests and ensure that each participant is tested at least once during their full course
of treatment. The informed consent taken during the enrollment includes the information
on the urine test. The urine is collected with a sterile container at the participants' home
and tested with the strip on the spot. The test results are recorded digitally.
For the control group, a similar measure will be taken to measure and observe the
adherence. Individuals who enrolled for TB preventive treatment will be randomly assigned
for urine tests, and urine will be collected at their home and tested and recorded on the
spot.
291
The medical technologists and community healthcare workers were trained centrally on
project activities, digital adherence monitoring on the "iDOTS" platform, patient enrollment,
and counseling. The project research officer alternately visits the facilities and supervises
the activities of medical technologists and community healthcare workers. One to two
DOTS providers from each DOTS facility were sensitized at the district level on the "iDOTS"
platform, patient enrollment, and counseling for understanding and supporting the overall
activity.
299
In the study's second phase, we will use the data from the "iDOTS" database to measure
the outcomes (adherence to TB preventive treatment and missed doses). Concurrently, we
will interview the same individuals to collect qualitative data from the providers and patients
using a semi-structured questionnaire. This part of the study wants to capture the human
experiences to augment the findings from the experiment. The providers and patients will
be interviewed to discuss their experiences and to capture the benefits and challenges of
"iDOTS."
307

308 ## Data management

309
310 This is a complex study with multiple components. All data will be collected with an
311 electronic tablet and saved in a cloud-based system. Research assistants will conduct the
312 interviews for the qualitative data collection. All interviews will be recorded with the
313 participant's consent. We will ensure privacy throughout the data collection and storage,
314 as per the requirements of the ethical review board.
315

316 ## Data analysis

317
318 The data analysis will be performed with the aim of assessing the effectiveness of "iDOTS",
319 to identify the variables that influence the uptake of this new technology, "iDOTS" along
320 with documentation of users' experience.
321

Quantitative data analysis:
To assess the effectiveness of "iDOTS", we will calculate the adherence rate to TB

preventive treatment, measured through multiple data sources: "iDOTS" dashboard data,
self-reported adherence, manually collected information, and urine sample iso-screen test
results. Adherence will be calculated as the percentage of doses taken relative to the total
prescribed, based on the "iDOTS" dashboard data. In addition, self-reported adherence will
be cross-checked with the urine sample results to assess self-reports' accuracy. The data
from the intervention group (using "iDOTS") will be compared to the control group (using
traditional methods) to determine the effectiveness of the "iDOTS" system in improving
adherence.

To assess differences in adherence between groups, we will first compute descriptive
statistics, including the mean, median, and standard deviation, to summarize the
adherence rates in both groups. Differences between the control and intervention groups
will be evaluated using the appropriate statistical tests, such as the Mann-Whitney U test
for non-parametric data or the independent t-test for normally distributed data. The focus
will be on the median number of missed doses, as well as the variance between self-
reported adherence and adherence confirmed by urine sample results.

In addition to basic group comparisons, regression analyses will be employed to identify
factors influencing adherence. Multiple linear regression will be used for continuous
outcomes (e.g., adherence rates), while logistic regression will be applied to examine
binary outcomes, such as whether a participant is adherent or non-adherent. These
regression models will help identify demographic and clinical variables that predict
adherence and allow for the identification of key factors that may influence the
effectiveness of the "iDOTS" technology.

Further, Partial Least Squares (PLS) regression will be applied to explore the relationships
between multiple predictors, including demographic factors, attitudes toward the
technology, and UTAUT constructs (performance expectancy, effort expectancy, social
influence, and facilitating conditions). PLS path modelling will allow us to assess these
constructs' direct and indirect effects on adherence behaviour. For instance, the analyses
will investigate how users' perceptions of the ease of use and perceived effectiveness of
"iDOTS" (effort expectancy and performance expectancy) influence their adherence to TB
preventive treatment. Similarly, the role of social influence (e.g., support from healthcare
providers, family, or peers) and facilitating conditions (e.g., availability of smartphones and
technical support) will be evaluated for their impact on technology uptake and adherence.

Qualitative Analysis:

The qualitative component will focus on capturing users' experiences, attitudes, and
perceptions of using "iDOTS". This will include exploring their satisfaction with the
technology, challenges faced during its use, and the broader social and logistical factors
that affect adoption. Semi-structured interviews will be conducted with participants to
understand the nuanced factors influencing their engagement with "iDOTS".

The qualitative data will be analyzed using thematic analysis, which involves identifying
and interpreting patterns (or themes) within the data. This process will include

familiarization with the data, generating initial codes, searching for themes, reviewing and refining themes, defining and naming themes, and reporting the findings. Key themes will likely emerge around areas such as ease of use, trust in the technology, perceived benefits and barriers, and external factors such as technical support and social influence.

These qualitative themes will provide deeper insight into the quantitative findings, particularly in terms of why certain demographic groups exhibit lower adherence rates or experience challenges with the technology.

Integrating Quantitative and Qualitative Data:

The integration of quantitative and qualitative data will provide a comprehensive understanding of the effectiveness of "iDOTS" and the factors that influence its uptake. The findings from both datasets will be merged through a process known as **data triangulation**, allowing for a more nuanced interpretation of the results. The combined analysis will enable us to assess how user experiences (captured qualitatively) explain or complement the patterns observed in the quantitative data.

For instance, if the quantitative data indicates that adherence rates are significantly higher in specific groups, qualitative data will be used to explore the reasons behind this success, such as user satisfaction, ease of use, or strong social support. Conversely, if certain groups show lower adherence, qualitative insights will help pinpoint the challenges they face—such as technological difficulties, lack of awareness, or social stigma—and suggest ways to overcome these barriers. This integration of findings will create a richer and more holistic picture of "iDOTS" impact on TPT adherence.

The joint display of quantitative and qualitative results will facilitate the comparison of adherence patterns with the underlying user experiences. For example, comparing adherence rates in different demographic groups can be placed alongside thematic insights related to trust, ease of use, or barriers to adoption. This will allow for a more direct comparison between how users experience the technology and its impact on their adherence behavior. It will provide insights into whether the technology is a scalable and effective solution for improving TB preventive treatment adherence in Bangladesh.

Ethical considerations and declarations

The protocol (PR-23001, version: 1.7, January 29, 2025) has been approved by icddr,b's Institutional Review Board, which includes both the Research Review Committee and the Ethical Review Committee. We have obtained permission from local health authorities and facilities, supported by a letter from the NTP for this project. Project staffs explain the study's purpose to participants and obtain their informed written consent. We will strictly maintain the confidentiality of participants regarding their health status and ensure data anonymity. Access to anonymous data will be limited to authorized health personnel, implementers, and participants.

Timeline

This study (excluding the product and protocol development) is planned to be implemented over a nine-month period, with a six-month enrollment period, three-month follow-up, data analysis, and write-up stage. We started enrolling participants on 01 October 2024. The tentative timeline for finishing enrollment was March/April 2025, and then a 03-month follow-up period to monitor adherence to TB preventative treatment medicine intake, along with data analysis and preparing the manuscript. As the study is ongoing, we expect that the enrollment of intervention and control participants will be completed by May 2025. We have already collected pre-intervention quantitative and qualitative data from providers and participants. We will start collecting post-intervention quantitative and qualitative data from May 2025 expect to complete by first week of June 2025. Data management with analysis will be completed simultaneously within the three-month follow-up period and expected result will be available by June 2025.

Discussion

The implementation of TB preventive treatment remains a relatively new and challenging territory for many low- and middle-income countries, particularly those burdened with high rates of TB, like Bangladesh. While TB preventive treatment implementation has gained momentum in countries with high HIV/AIDS prevalence, where it is easier to integrate into existing healthcare systems through platforms that track and counsel individuals, the situation in Bangladesh presents unique challenges. In countries like Bangladesh, where healthcare infrastructure is still developing, scaling TB preventive treatment across a large population becomes more complicated, requiring technological solutions and systemic changes in healthcare delivery.

It has been over five years since the United Nations High-Level Meeting on TB, where member states committed to implementing TB preventive treatment nationally [17]. However, data from various countries, including Bangladesh, indicate that progress has been slow. While the COVID-19 pandemic is often cited as a major disruptor to TB services, and the high cost of shorter drug regimens is a significant financial barrier, there are also other underlying issues hindering the large-scale implementation of TB preventive treatment. A key factor contributing to this slow pace of implementation is the lack of sufficient tools and evidence that can guide and support countries in scaling up their TB preventive treatment efforts [18].

In Bangladesh, where the need for innovative solutions is critical, locally developed tools such as the "iDOTS" system can potentially fill some of the gaps in the existing healthcare infrastructure. However, while the effectiveness of such tools is still largely unknown, this tool, "iDOTS" could serve as a valuable resource for improving the monitoring and reporting of TB preventive treatment adherence. By enabling the remote monitoring of medication intake, "iDOTS" could provide real-time data on treatment adherence, identify gaps in care, and help reduce the risk of treatment failure. In this context, "iDOTS" could serve as an

adherence tool and a mechanism for identifying adverse events and monitoring treatment
progress.

Despite the potential benefits, adopting such a locally developed technological solution is
not without barriers for most low- middle income countries. Bangladesh's diverse
healthcare landscape, coupled with varying levels of technological infrastructure and
literacy, presents a set of challenges to the widespread uptake of digital tools like "iDOTS".
Although the technology is relatively simple, its acceptance and integration into the daily
lives of healthcare providers and patients may be hindered by issues such as limited access
to smartphones, internet connectivity problems, and resistance to adopting new
technologies in rural areas. Additionally, healthcare workers lack awareness and training,
which could limit their ability to leverage such tools effectively.

The UTAUT (Unified Theory of Acceptance and Use of Technology) provides a useful
framework for understanding technology acceptance. Still, it accounts for only about
seventy percent of the variance in user acceptance [14]. This suggests that other factors
at play influence the decision to adopt and use technologies like "iDOTS". The first phase
of this mixed-methods study aims to identify additional constructs beyond those specified
by UTAUT, which could help improve predictions of technology adoption and usage
behaviour. Qualitative interviews can help us identify such variables. By incorporating these
additional factors into the UTAUT framework, this study will contribute empirical evidence
to refine and expand the theory, particularly in TB treatment in low-resource settings.

One of the most pressing issues in the implementation of TB preventive treatment is the
uncertainty around whether people are taking their medication consistently and whether
counselling efforts are adequate. Despite the substantial resources allocated to TB
preventive treatment, there is still a significant knowledge gap regarding the actual number
of people taking the medicine, the rate of treatment dropouts, and whether the preventive
therapy is achieving the intended public health impact. "iDOTS" could potentially bridge this
gap by providing more accurate and timely data on treatment adherence and by offering a
platform for continuous counselling and support. However, to fully understand its potential,
further studies are needed to assess its effectiveness in real-world settings, particularly in
countries with limited healthcare infrastructure like Bangladesh.

Moreover, as we begin to integrate such technologies into TB programs, it is critical to
monitor the adherence rates and the broader social and contextual factors that influence
treatment uptake. This includes the level of trust patients have in the healthcare system,
the perceived stigma associated with TB, and the adequacy of healthcare resources
available for remote consultations. It is essential that any technological intervention also be
accompanied by efforts to address these broader barriers to care in order to achieve
meaningful improvements in public health outcomes.

While "iDOTS" represents a promising tool for enhancing TB preventive treatment
implementation in Bangladesh, its effectiveness in improving adherence will ultimately
depend on how well it can be integrated into the existing healthcare system. The evidence

generated from this study could serve as a foundation for scaling up this tool, providing a
critical resource for monitoring TB treatment adherence, and ultimately improving patient
outcomes. However, as we move forward, it is important to recognize that the journey
towards large-scale TB preventive treatment implementation is complex and requires
multifaceted solutions, including but not limited to technological innovations like "iDOTS".

Ultimately, this study aims to assess the potential of "iDOTS" in improving adherence and contribute to the broader conversation about how low- and middle-income countries can better implement TB preventive treatment. The findings from this study will provide valuable insights into the barriers and enablers of technology adoption in healthcare settings, particularly in contexts like Bangladesh, where both technological infrastructure and public health systems are still evolving. By refining the UTAUT framework and incorporating additional contextual factors, this research will help pave the way for more effective and scalable TB prevention efforts in high-burden countries.

Authors' contributions

Pushpita Samina

Roles: conceptualization, supervision, writing – original draft, editing

Md Rifat Haidar

Roles: writing- original draft, editing, data collection, implementation

Tasmia Ibrahim

Roles: conceptualization, editing, implementation

Tanjina Rahman

Roles: conceptualization, editing and data management

Mohammad Shahnewaz Sarker

Roles: product development, troubleshooting

Dr. Syada Samsia Noor

Roles: data collection and monitoring

Dr. Shahriar Ahmed

Roles: editing, supervision and troubleshooting

Dr. Mohammad Khaja Mafij Uddin

Roles: supervision and monitoring

Dr. Senjuti Kabir

Roles: conceptualization, editing, supervision and troubleshooting

Dr Sayera Banu

Roles: conceptualization, editing, supervision and overall monitoring

Acknowledgements

We acknowledge the Stop TB partnership for funding and thank to the NTP, local

healthcare authorities and the study participants for their contribution.

This research protocol/study was funded by core donors who provide unrestricted support to icddr,b for its operations and research. Current donors providing unrestricted support include the Governments of Bangladesh and Canada. We gratefully acknowledge our core donors for their support and commitment to icddr,b's research efforts.

Supporting Information

S1 Fig-1. TPT algorithm of National TB control program

S2 Fig-2. Diagram of iDOTS study design

S3 Participant enrollment questionnaire for intervention and control site

S4 Pre-intervention survey questionnaire for providers

S5 Pre-intervention survey questionnaire for study participants

S6 Post-intervention survey questionnaire for providers

S7 Post-intervention survey questionnaire for study participants

References

1. Kiazyk S, Ball TB. Latent tuberculosis infection: An overview. Can Commun Dis Rep. 2017;43(3-4):62-6. Epub 20170302. doi: 10.14745/ccdr.v43i34a01. PubMed PMID: 29770066; PubMed Central PMCID: PMCPMC5764738.

2. Organization WH. WHO operational handbook on tuberculosis. 2024 September 9. Report No.

3. Organization WH, Control CfD, Prevention. Tuberculosis prevention and care among refugees and other populations in humanitarian settings: an interagency field guide. 2022.

4. Timothy R. Sterling MGN, MPH; Dominik Zenner, MD; David L. Cohn, MD; Randall Reves, MD; Amina Ahmed, MD; Dick Menzies, MD; C. Robert Horsburgh Jr., MD; Charles M. Crane, MD; Marcos Burgos, MD; Philip LoBue, MD; Carla A. Winston, PhD; Robert Belknap, MD. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recommendations and Reports. 2020. doi: http://dx.doi.org/10.15585/mmwr.rr6901a1.

5. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS medicine. 2016;13(10):e1002152.

6. Rahman MT, Hossain F, Banu RS, Islam MS, Alam S, Faisel AJ, et al. Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid–Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study. Tropical Medicine and Infectious Disease. 2023;9(1):4.

7. Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018;51(1). Epub 20180111. doi: 10.1183/13993003.01596-2017. PubMed PMID: 29326332;

PubMed Central PMCID: PMCPMC5764088.

8. Efo E, Onjare B, Shilugu L, Levy J, editors. Acceptability, Feasibility and Accuracy of 99DOTS
Adherence Technology in Mining Region of Tanzania. 2021 IST-Africa Conference (IST-Africa);
2021: IEEE.

9. Thomas BE, Kumar JV, Chiranjeevi M, Shah D, Khandewale A, Thiruvengadam K, et al.
Evaluation of the Accuracy of 99DOTS, a Novel Cellphone-based Strategy for Monitoring
Adherence to Tuberculosis Medications: Comparison of DigitalAdherence Data With Urine
Isoniazid Testing. Clin Infect Dis. 2020;71(9):e513-e6. doi: 10.1093/cid/ciaa333. PubMed PMID:
32221550; PubMed Central PMCID: PMCPMC7713673.

10. Cross A, Gupta N, Liu B, Nair V, Kumar A, Kuttan R, et al., editors. 99DOTS: a low-cost
approach to monitoring and improving medication adherence. Proceedings of the Tenth
International Conference on Information and Communication Technologies and Development;
2019.

11. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, et al. Protocol for the
3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery
strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
Implementation Science. 2020;15:1-12.

12. Rutherford ME, Ruslami R, Maharani W, Yulita I, Lovell S, Van Crevel R, et al. Adherence to
isoniazid preventive therapy in Indonesian children: a quantitative and qualitative investigation.
BMC research notes. 2012;5:1-7.

13. Thekkur P, Kumar AM, Chinnakali P, Selvaraju S, Bairy R, Singh AR, et al. Outcomes and
implementation challenges of using daily treatment regimens with an innovative adherence support
tool among HIV-infected tuberculosis patients in Karnataka, India: a mixed-methods study. Global
health action. 2019;12(1):1568826.

14. Venkatesh V, Morris MG, Davis GB, Davis FD. User acceptance of information technology:
Toward a unified view. MIS quarterly. 2003:425-78.

15. Enam A, Torres-Bonilla J, Eriksson H. Evidence-based evaluation of eHealth interventions:
systematic literature review. Journal of medical Internet research. 2018;20(11):e10971.

16. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger CA, Lamunu M, et al.
Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-
susceptible TB in Uganda. PLOS Digital Health. 2023;2(6):e0000138.

17. Millington KA, White RG, Lipman M, McQuaid CF, Hauser J, Wooding V, et al. The 2023 UN
high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end
tuberculosis. The Lancet Respiratory Medicine. 2024;12(1):10-3.

18. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.